Reply to Xuefeng Liu's Letter to the Editor, re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430-4: Can Patient-derived Cancer Models Change the Costliest Cancer Type?
1 Institute of Biomedicine, University of Turku, and Department of Pathology, Turku University Hospital, Turku, Finland.
2 Department of Urology, Turku University Hospital and University of Turku, Turku, Finland.
3 Institute of Biomedicine, University of Turku, and Department of Pathology, Turku University Hospital, Turku, Finland. Electronic address: pekka.taimen@utu.fi.